29 patents
Utility
Methods of Improving Renal Function
16 Nov 23
Provided herein are methods of improving kidney function in a subject in need thereof.
Philip Thomas Frohlich, Andrew James King, Chidambaram Ramachandran, Sarah Beth Noonberg
Filed: 18 Jul 23
Utility
Methods of Reducing Disease Flares
9 Nov 23
Provided herein are methods of reducing the incident of disease flares in a subject in need thereof.
Philip Thomas Frohlich, Andrew James King, Chidambaram Ramachandran, Sarah Beth Noonberg
Filed: 18 Jul 23
Utility
Methods of Improving Renal Function
9 Nov 23
Provided herein are methods of improving kidney function in a subject in need thereof.
Philip Thomas Frohlich, Andrew James King, Chidambaram Ramachandran, Sarah Beth Noonberg
Filed: 18 Jul 23
Utility
Methods of Treating Diabetic Kidney Disease
31 Aug 23
Provided herein are methods of treating diabetic kidney disease comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, and a SGLT-2 inhibitor to a subject in need thereof.
Joel Z. Melnick, Michael G. Miller, Tingting YI, Hiddo Lambers Heerspink, Andrew James King, Sarah B. Noonberg
Filed: 12 Apr 21
Utility
Methods of Improving Renal Function
27 Apr 23
Provided herein are methods of improving kidney function in a subject in need thereof.
Philip Thomas Frohlich, Andrew James King, Chidambaram Ramachandran, Sarah Beth Noonberg
Filed: 16 Aug 22
Utility
Methods of improving renal function
8 Nov 22
Provided herein are methods of improving kidney function in a subject in need thereof.
Philip Thomas Frohlich, Andrew James King, Chidambaram Ramachandran, Sarah Beth Noonberg
Filed: 27 May 22
Utility
Pyridinyl Indole Compounds and Methods of Use Thereof
27 Oct 22
Provided herein are compounds for the treatment or prevention of AMPK-(5′ adenosine monophosphate-activated protein kinase) mediated diseases.
Jinyue DING, Robert GOMEZ, James Gifford GUTHRIE, David Andrew POWELL, Tao SHENG
Filed: 6 Apr 22
Utility
Inhibiting Mesangial Cell Activation
29 Sep 22
Provided herein are methods of inhibiting mesangial cell activation in a subject in need thereof.
Philip Thomas Frohlich, Andrew James King, Chidambaram Ramachandran, Sarah Beth Noonberg
Filed: 27 May 22
Utility
Methods of Reducing Disease Flares
29 Sep 22
Provided herein are methods of reducing the incident of disease flares in a subject in need thereof.
Philip Thomas Frohlich, Andrew James King, Chidambaram Ramachandran, Sarah Beth Noonberg
Filed: 27 May 22
Utility
Methods of Treating Kidney Diseases
15 Sep 22
Provided herein are methods of treating kidney diseases in a subject in need thereof.
Philip Thomas Frohlich, Andrew James King, Chidambaram Ramachandran, Sarah Beth Noonberg
Filed: 27 May 22
Utility
Methods of Improving Renal Function
15 Sep 22
Provided herein are methods of improving kidney function in a subject in need thereof.
Philip Thomas Frohlich, Andrew James King, Chidambaram Ramachandran, Sarah Beth Noonberg
Filed: 27 May 22
Utility
Anti-sirp Alpha Antibodies
5 May 22
The present invention relates to anti-SIRPα antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
Hans VAN EENENNAAM, Andrea VAN ELSAS, Erik VOETS, Paul VINK, David Lutje HULSIK
Filed: 30 Nov 20
Utility
METHODS OF TREATING IgA NEPHROPATHY WITH AN APRIL BINDING ANTIBODY
9 Dec 21
Formulation and use of antibodies which bind human APRIL for the treatment of conditions related to IgA overproduction or deposition, including IgA Nephropathy.
Teun VAN DE LAAR, Somayeh HONARMAND, John DULOS, Eduard DE COCK
Filed: 28 May 21
Utility
Methods of Treating Iga Nephropathy with Atrasentan
18 Nov 21
Provided herein are methods of treating IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
Philip Thomas Frohlich, Andrew James King, Chidambaram Ramachandran, Sarah Beth Noonberg
Filed: 30 Jun 21
Utility
Methods for Performing Ex Vivo Diagnostic Tests for the Presence of a Proliferation-inducing Ligand (April) In a Human Sample
21 Oct 21
The invention relates to a method for obtaining APRIL-binding peptides.
Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
Filed: 28 Jun 21
Utility
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
24 Aug 21
The present invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes).
David Braun Kanne, Chudi Obioma Ndubaku, Jacob Robert Bruml, Thanh Ngoc Lan Le, Jeffrey McKenna, George Scott Tria, Stephen Canham
Filed: 1 Jul 17
Utility
Altered April Binding Antibodies
22 Jul 21
The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A.
Hans Van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
Filed: 29 Mar 21
Utility
Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a human sample
29 Jun 21
The invention relates to a method for obtaining APRIL-binding peptides.
Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
Filed: 11 Sep 18
Utility
Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling
22 Jun 21
The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes).
George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.
Filed: 21 Oct 19
Utility
Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof
13 Apr 21
The present invention provides the cyclic dinucleotide compound 2′2′-RR-(3′F-A)(3′F-A) as a highly active immune stimulator that activates DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes), and compositions and uses thereof.
Justin Leong, Chudi Obioma Ndubaku, Jeffrey McKenna
Filed: 26 Apr 18